Comparison of efficacy and safety of vancomycin and linezolid for central nervous system infections
OBJECTIVE To explore the efficacy and safety of vancomycin versus linezolid for central nervous system infec-tions(CNSIs)and provide a practical reference of real-world data for clinical treatment.METHODS For this retrospective cohort study,the relevant clinical data were reviewed for 155 CNSIs patients.They were divided into two groups of vancomycin(n=76)and linezolid(n=79).The inter-group differences in efficacy(in-hospital mortality,abandoning therapy incidence & clini-cal effective rate)and safety(total adverse reaction,renal dysfunction,liver dysfunction & hematologic disorder)were compared.RESULTS The abandoning therapy incidence of linezolid group was significantly higher than that of vancomycin group(27.8％vs 10.5％,P=0.006).Clinical effective rate of vancomycin group was significantly higher than that of linezolid group(81.6％vs 63.3％,P=0.011).All outcomes of safety between two groups was not statistically significant(P＞0.05).Univariate and multi-variate Logistic regression analyses revealed that use of vancomycin(OR=2.274,P=0.036)and a combined dosing of merope-nem(OR=2.949,P=0.030)or cefoperazone-sulbactam(OR=4.403,P=0.010)were associated independently with clinical effi-cacy.CONCLUSION As compared with linezolid,vancomycin offers superior efficacy and comparable safety for CNSIs.Use of vancomycin and a combined dosing of meropenem or cefoperazone-sulbactam are favorable factors of clinical efficacy.
vancomycinlinezolidcentral nervous system infectionsefficacysafety
NETL
NSTL
万方数据
